Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Termedia Publishing House
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fa35fde7f1a7446d9d954c25e26d2d8f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:fa35fde7f1a7446d9d954c25e26d2d8f |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:fa35fde7f1a7446d9d954c25e26d2d8f2021-12-02T19:19:18ZTolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study1428-25261897-430910.5114/wo.2020.102802https://doaj.org/article/fa35fde7f1a7446d9d954c25e26d2d8f2021-01-01T00:00:00Zhttps://www.termedia.pl/Tolerability-and-outcome-of-sunitinib-by-giving-4-2-schedule-versus-2-1-schedule-in-metastatic-renal-cell-carcinoma-patients-a-prospective-randomized-multi-centric-Egyptian-study,3,43068,1,1.htmlhttps://doaj.org/toc/1428-2526https://doaj.org/toc/1897-4309Lobna A. AbdelazizHeba F. TahaMagid M. AliMarwa I. AbdelgawadAmira ElwanTermedia Publishing Housearticlemetastatic renal cell carcinoma sunitinib 4/2 schedule 2/1 schedule adverse events outcome.MedicineRENContemporary Oncology, Vol 24, Iss 4, Pp 221-228 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
metastatic renal cell carcinoma sunitinib 4/2 schedule 2/1 schedule adverse events outcome. Medicine R |
| spellingShingle |
metastatic renal cell carcinoma sunitinib 4/2 schedule 2/1 schedule adverse events outcome. Medicine R Lobna A. Abdelaziz Heba F. Taha Magid M. Ali Marwa I. Abdelgawad Amira Elwan Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study |
| format |
article |
| author |
Lobna A. Abdelaziz Heba F. Taha Magid M. Ali Marwa I. Abdelgawad Amira Elwan |
| author_facet |
Lobna A. Abdelaziz Heba F. Taha Magid M. Ali Marwa I. Abdelgawad Amira Elwan |
| author_sort |
Lobna A. Abdelaziz |
| title |
Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study |
| title_short |
Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study |
| title_full |
Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study |
| title_fullStr |
Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study |
| title_full_unstemmed |
Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study |
| title_sort |
tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric egyptian study |
| publisher |
Termedia Publishing House |
| publishDate |
2021 |
| url |
https://doaj.org/article/fa35fde7f1a7446d9d954c25e26d2d8f |
| work_keys_str_mv |
AT lobnaaabdelaziz tolerabilityandoutcomeofsunitinibbygiving42scheduleversus21scheduleinmetastaticrenalcellcarcinomapatientsaprospectiverandomizedmulticentricegyptianstudy AT hebaftaha tolerabilityandoutcomeofsunitinibbygiving42scheduleversus21scheduleinmetastaticrenalcellcarcinomapatientsaprospectiverandomizedmulticentricegyptianstudy AT magidmali tolerabilityandoutcomeofsunitinibbygiving42scheduleversus21scheduleinmetastaticrenalcellcarcinomapatientsaprospectiverandomizedmulticentricegyptianstudy AT marwaiabdelgawad tolerabilityandoutcomeofsunitinibbygiving42scheduleversus21scheduleinmetastaticrenalcellcarcinomapatientsaprospectiverandomizedmulticentricegyptianstudy AT amiraelwan tolerabilityandoutcomeofsunitinibbygiving42scheduleversus21scheduleinmetastaticrenalcellcarcinomapatientsaprospectiverandomizedmulticentricegyptianstudy |
| _version_ |
1718376890861879296 |